Federal Register Notice: FDA has determined the regulatory review period for Dyax Corp.’s Kalbitor (ecallantide) is 2,855 days for extending a patent which claims the human biological product. Kalbitor is indicated for treating acute attacks of hereditary angioedema in patients 16 years of age and older. To view this notice, click here.
